Plasma Derived Therapy Market - Top Companies and Manufacturers

Companies Dominating the Plasma Derived Therapy Landscape

The major players in the plasma derived therapy market are offering a detailed portfolio of demand for plasma-derived products. These companies are developing and delivering high-quality medicines and therapies using plasma that treat people with rare and serious diseases.

CSL Behring
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

ADMA Biologics, Inc.
Bio Products Laboratory Ltd.
Biotest AG
Grifols, SA
Kedrion S.p.A
Octapharma AG
Pfizer Inc.
SK Plasma
Kamada Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Plasma Derived Therapy Market Size - Growth Analysis 2036

In the News

CSL Behring company along with its partner Akebia Therapeutics, Inc. has announced that they have received U.S. Food and Drug Administration (FDA) approval for Vafseo (vadadustat) tablets which were given for the treatment of anemia caused due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
ADMA Biologics, Inc. received the United States Food and Drug Administration’s (FDA) approval for its supplemental Biologics License Applications (BLAs) for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature (25°C) storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life.

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of plasma-derived therapy was over USD 23 billion.

The market size for plasma-derived therapy is projected to cross USD 56 billion by the end of 2036 expanding at a CAGR of 8% during the forecast period i.e., between 2024-2036.

The major players in the market are CSL Behring, ADMA Biologics, Inc., Bio Products Laboratory Ltd., Biotest AG, Grifols, SA, Kedrion S.p.A, Octapharma AG, Pfizer Inc., SK Plasma, Kamada Pharmaceuticals, and others.

The immunoglobulins segment is anticipated to garner a share/size of 49% during 2024-2036.

The North America plasma-derived therapy sector is poised to hold a 34% share by the end of 2036.

Plasma Derived Therapy Market - Top Companies and Manufacturers

Companies Dominating the Plasma Derived Therapy Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the plasma-derived therapy industry?

What is the outlook for the plasma-derived therapy market?

Who are the major players dominating the plasma-derived therapy landscape?

Which segment will capture the significant market share for plasma-derived therapy by 2036?

Which region will provide more opportunities for the plasma-derived therapy business in the near future?